Dr. Henrike Lucas
Dr. Henrike Lucas
Pharm. Technology & Biopharmacy
EG, Room 158
Kurt-Mothes-Str. 3
D-06120 Halle/Saale
Tel. +49 345 55 25 133
Fax +49 345 55 27 029
e-mail: henrike.lucas(at)pharmazie.uni-halle.de
Curriculum Vitae
Curriculum Vitae - Dr. rer. nat. Henrike Lucas
Curriculum Vitae - Dr. rer. nat. Henrike Lucas.pdf
(149.1 KB) vom 31.07.2020
Publications
Caysa H. Untersuchungen zum Monitoring von Tumorxenograftmodellen mittels nicht-invasivem in vivo Multispektral-Fluoreszenzimaging. Dissertation, 2013. Link:http://digital.bibliothek.uni-halle.de/hs/content/ titleinfo/1630519.
1: Klein ME, Rieckmann M, Lucas H, Meister A, Loppnow H, Mäder K. Phosphatidylserine (PS) and phosphatidylglycerol (PG) enriched mixed micelles (MM): A new nano-drug delivery system with anti-inflammatory potential? Eur J Pharm Sci. 2020 Jul 2;152:105451. doi: 10.1016/j.ejps.2020.105451. Online ahead of print. PMID: 32621969.
2: Busmann EF, Martínez DG, Lucas H, Mäder K. Phase inversion-based nanoemulsions of medium chain triglyceride as potential drug delivery system for parenteral applications. Beilstein J Nanotechnol. 2020 Jan 17;11:213-224. doi: 10.3762/bjnano.11.16. eCollection 2020. PMID: 32082961.
3: Klein ME, Mauch S, Rieckmann M, Martínez DG, Hause G, Noutsias M, Hofmann U, Lucas H, Meister A, Ramos G, Loppnow H, Mäder K. Phosphatidylserine (PS) and phosphatidylglycerol (PG) nanodispersions as potential anti-inflammatory therapeutics: Comparison of in vitro activity and impact of pegylation. Nanomedicine. 2020 Jan;23:102096. doi: 10.1016/j.nano.2019.102096. Epub 2019 Oct 25. PMID: 31669855.
4: Mueller T, Freystein J, Lucas H, Schmoll HJ. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model. Molecules. 2019 Aug 7;24(16):2865. doi: 10.3390/molecules24162865. PMID: 31394786.
5: Riehl M, Harms M, Lucas H, Ebensen T, Guzmán CA, Mäder K. Dual dye in-vivo imaging of differentially charged PLGA carriers reveals antigen-depot effect, leading to improved immune responses in preclinical models. Eur J Pharm Sci. 2018 May 30;117:88-97. doi: 10.1016/j.ejps.2018.01.040. Epub 2018 Feb 13. PubMed PMID:29408551.
6: Weiss VM, Lucas H, Mueller T, Chytil P, Etrych T, Naolou T, Kressler J, Mäder K. Intended and Unintended Targeting of Polymeric Nanocarriers: The Case of Modified Poly(glycerol adipate) Nanoparticles. Macromol Biosci. 2018 Jan;18(1). doi: 10.1002/mabi.201700240. Epub 2017 Dec 8. PubMed PMID: 29218838.
7: Lomkova EA, Chytil P, Janoušková O, Mueller T, Lucas H, Filippov SK, Trhlíková O, Aleshunin PA, Skorik YA, Ulbrich K, Etrych T. Biodegradable Micellar HPMA-Based Polymer-Drug Conjugates with Betulinic Acid for Passive Tumor Targeting. Biomacromolecules. 2016 Nov 14;17(11):3493-3507. doi: 10.1021/acs.biomac.6b00947. Epub 2016 Sep 30. PMID: 27636143.
8: Heinrich AK, Lucas H, Schindler L, Chytil P, Etrych T, Mäder K, Mueller T. Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance. Mol Cancer Ther. 2016 May;15(5):998-1007. doi: 10.1158/1535-7163.MCT-15-0824. Epub 2016 Mar 3. PubMed PMID: 26939698.
9: Etrych T, Lucas H, Janoušková O, Chytil P, Mueller T, Mäder K. Fluorescence optical imaging in anticancer drug delivery. J Control Release. 2016 Mar 28;226:168-81. doi: 10.1016/j.jconrel.2016.02.022. Epub 2016 Feb 16. Review. PubMed PMID: 26892751.
10: Surov A, Caysa H, Wienke A, Spielmann RP, Fiedler E. Correlation Between Different ADC Fractions, Cell Count, Ki-67, Total Nucleic Areas and Average Nucleic Areas in Meningothelial Meningiomas. Anticancer Res. 2015 Dec;35(12):6841-6. PubMed PMID: 26637905.
11: Widder M, Lützkendorf J, Caysa H, Unverzagt S, Wickenhauser C, Benndorf RA, Schmoll HJ, Müller-Tidow C, Müller T, Müller LP. Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β1-integrin-dependent mechanism. Int J Cancer. 2016 Feb 15;138(4):964-75. doi: 10.1002/ijc.29844. Epub 2015 Oct 1. PubMed PMID: 26356035.
12: Mahal K, Biersack B, Caysa H, Schobert R, Mueller T. Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation. Invest New Drugs. 2015 Jun;33(3):541-54. doi: 10.1007/s10637-015-0215-9. Epub 2015 Feb 14. PubMed PMID: 25678082.
13: Chytil P, Hoffmann S, Schindler L, Kostka L, Ulbrich K, Caysa H, Mueller T, Mäder K, Etrych T. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution. J Control Release. 2013 Dec 10;172(2):504-12. doi: 10.1016/j.jconrel.2013.05.008. Epub 2013 May 19. PubMed PMID: 23697767.
14: Hoffmann S, Caysa H, Kuntsche J, Kreideweiss P, Leimert A, Mueller T, Mäder K. Carbohydrate plasma expanders for passive tumor targeting: in vitro and in vivo studies. Carbohydr Polym. 2013 Jun 5;95(1):404-13. doi: 10.1016/j.carbpol.2013.03.033. Epub 2013 Mar 15. PubMed PMID: 23618286.
15: Caysa H, Hoffmann S, Luetzkendorf J, Mueller LP, Unverzagt S, Mäder K, Mueller T. Monitoring of xenograft tumor growth and response to chemotherapy by non-invasive in vivo multispectral fluorescence imaging. PLoS One. 2012;7(10):e47927. doi: 10.1371/journal.pone.0047927. Epub 2012 Oct 24. PubMed PMID: 23112873; PubMed Central PMCID: PMC3480443.
16: Schädlich A, Hoffmann S, Mueller T, Caysa H, Rose C, Göpferich A, Li J, Kuntsche J, Mäder K. Accumulation of nanocarriers in the ovary: a neglected toxicity risk? J Control Release. 2012 May 30;160(1):105-12. doi: 10.1016/j.jconrel.2012.02.012. Epub 2012 Feb 21. PubMed PMID: 22361117.
17: Hoffmann S, Vystrčilová L, Ulbrich K, Etrych T, Caysa H, Mueller T, Mäder K. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release: synthesis and characterization of distribution and tumor accumulation in mice by noninvasive multispectral optical imaging. Biomacromolecules. 2012 Mar 12;13(3):652-63. doi: 10.1021/bm2015027. Epub 2012 Feb 10. PubMed PMID: 22263698.
18: Schädlich A, Caysa H, Mueller T, Tenambergen F, Rose C, Göpferich A, Kuntsche J, Mäder K. Tumor accumulation of NIR fluorescent PEG-PLA nanoparticles: impact of particle size and human xenograft tumor model. ACS Nano. 2011 Nov 22;5(11):8710-20. doi: 10.1021/nn2026353. Epub 2011 Oct 10. PubMed PMID: 21970766.
19: Caysa H, Metz H, Mäder K, Mueller T. Application of Benchtop-magnetic resonance imaging in a nude mouse tumor model. J Exp Clin Cancer Res. 2011 Jul 21;30(1):69. doi: 10.1186/1756-9966-30-69. PubMed PMID: 21777437; PubMed Central PMCID: PMC3158420.
20: Schädlich A, Rose C, Kuntsche J, Caysa H, Mueller T, Göpferich A, Mäder K. How stealthy are PEG-PLA nanoparticles? An NIR in vivo study combined with detailed size measurements. Pharm Res. 2011 Aug;28(8):1995-2007. doi: 10.1007/s11095-011-0426-5. Epub 2011 Apr 27. PubMed PMID: 21523513.
21: Besheer A, Caysa H, Metz H, Mueller T, Kressler J, Mäder K. Benchtop-MRI for in vivo imaging using a macromolecular contrast agent based on hydroxyethyl starch (HES). Int J Pharm. 2011 Sep 30;417(1-2):196-203. doi: 10.1016/j.ijpharm.2010.10.051. Epub 2010 Nov 5. PubMed PMID: 21056646.
22: Mueller LP, Luetzkendorf J, Widder M, Nerger K, Caysa H, Mueller T. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther. 2011 Apr;18(4):229-39. doi: 10.1038/cgt.2010.68. Epub 2010 Oct 29. PubMed PMID: 21037557.
23: Luetzkendorf J, Mueller LP, Mueller T, Caysa H, Nerger K, Schmoll HJ. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. J Cell Mol Med. 2010 Sep;14(9):2292-304. doi: 10.1111/j.1582-4934.2009.00794.x. PubMed PMID: 19508388; PubMed Central PMCID: PMC3822570.
24: Caysa H, Jacob R, Müther N, Branchini B, Messerle M, Söling A. A redshifted codon-optimized firefly luciferase is a sensitive reporter for bioluminescence imaging. Photochem Photobiol Sci. 2009 Jan;8(1):52-6. doi: 10.1039/b814566k. Epub 2008 Oct 29. PubMed PMID: 19247529.